Inflammatory Breast Cancer Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Immune pathogenesis of idiopathic granulomatous mastitis: from etiology toward therapeutic approaches
Idiopathic granulomatous mastitis (IGM) is a noncancerous, chronic inflammatory disorder of breast with unknown causes, posing significant challenges to the quality of life due to its high refractoriness and local aggressiveness. The typical symptoms of this disease involve skin redness, a firm and tender breast mass and mastalgia; others may include swelling, fistula, abscess (often without fever), nipple retraction, and peau d’orange appearance. IGM often mimics breast abscesses or malignancies, particularly inflammatory breast cancer, and is characterized by absent standardized treatment options, inconsistent patient ...
Source: Frontiers in Immunology - March 11, 2024 Category: Allergy & Immunology Source Type: research

New Strategies for Locally Advanced Breast Cancer: A Review of Inflammatory Breast Cancer and Nonresponders
Clin Breast Cancer. 2024 Jan 21:S1526-8209(24)00009-0. doi: 10.1016/j.clbc.2024.01.009. Online ahead of print.ABSTRACTThis review explores the new strategies around the management of locally advanced breast cancer (LABC), particularly for nonresponsive tumors and/or initially unresectable tumors at diagnosis, inclusive of inflammatory breast cancer. Nonresponders to neoadjuvant systemic therapy present a unique clinical challenge. Emerging medical therapeutics as well as considerations for use of radiotherapy and/or surgery in this setting are discussed. Specifically, the use of neoadjuvant radiotherapy for LABC and lymphe...
Source: Clinical Breast Cancer - March 2, 2024 Category: Cancer & Oncology Authors: Simran Malhotra Audree B Tadros Source Type: research

New Strategies for Locally Advanced Breast Cancer: A Review of Inflammatory Breast Cancer and Nonresponders
Clin Breast Cancer. 2024 Jan 21:S1526-8209(24)00009-0. doi: 10.1016/j.clbc.2024.01.009. Online ahead of print.ABSTRACTThis review explores the new strategies around the management of locally advanced breast cancer (LABC), particularly for nonresponsive tumors and/or initially unresectable tumors at diagnosis, inclusive of inflammatory breast cancer. Nonresponders to neoadjuvant systemic therapy present a unique clinical challenge. Emerging medical therapeutics as well as considerations for use of radiotherapy and/or surgery in this setting are discussed. Specifically, the use of neoadjuvant radiotherapy for LABC and lymphe...
Source: Clinical Genitourinary Cancer - March 2, 2024 Category: Cancer & Oncology Authors: Simran Malhotra Audree B Tadros Source Type: research

Should breast surgery be considered for patients with de novo metastatic inflammatory breast cancer?
We aimed to identify factors predicting surgery for de novo stage IV inflammatory breast cancer (IBC) and determine the association of surgery with overall survival (OS). (Source: American Journal of Surgery)
Source: American Journal of Surgery - March 1, 2024 Category: Surgery Authors: Lauren M. Drapalik, Robert Shenk, Lisa Rock, Ashley Simpson, Amanda L. Amin, Megan E. Miller Tags: Original Research Article Source Type: research

XIAP overexpressing inflammatory breast cancer patients have high infiltration of immunosuppressive subsets and increased TNFR1 signaling targetable with Birinapant
CONCLUSION: Using immunophenotyping and gene expression analysis in patient biospecimens along with in silico modeling and a preclinical model with a pan-IAP antagonist, this study revealed an interplay between increased TAMs, TNF-α signaling, and XIAP activation during (immune) stress in IBC. These data demonstrate the potential of IAP antagonists as immunomodulators for improving IBC therapeutic regimens.PMID:38412664 | DOI:10.1016/j.tranon.2024.101907 (Source: Translational Oncology)
Source: Translational Oncology - February 27, 2024 Category: Cancer & Oncology Authors: Christophe Van Berckelaer Steven Van Laere Seayoung Lee Michael A Morse Joseph Geradts Luc Dirix Mark Kockx Fran çois Bertucci Peter Van Dam Gayathri R Devi Source Type: research

Conserving surgery in inflammatory breast cancer after neoadjuvant chemotherapy in patients with clinical complete response: the ConSIBreC randomized controlled trial
(Source: Frontiers in Oncology)
Source: Frontiers in Oncology - February 22, 2024 Category: Cancer & Oncology Source Type: research

GSE232764 TBCRC 039: A phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer
Contributors : Filipa Lynce ; Laura Stevens ; Zheqi Li ; Kornelia PolyakSeries Type : Expression profiling by high throughput sequencingOrganism :We conducted a randomized phase II study with nested window-of-opportunity in patients with TN-IBC. Patients were randomized to receive a 7-day run-in of ruxolitinib (RUX) alone or ruxolitinib plus paclitaxel (RUX+PAC) in a 1:2 ratio, followed by 12 weeks of neoadjuvant paclitaxel alone or in combination with ruxolitinib in a 1:2 ratio. All patients subsequently received 4 cycles of doxorubicin plus cyclophosphamide, followed by modified radical mastectomy. Patients provided ...
Source: GEO: Gene Expression Omnibus - February 7, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Source Type: research

Bilateral inflammatory recurrence of HER-2 positive breast cancer: a unique case report and literature review
Inflammatory breast cancer (IBC) is an aggressive and rare form of breast cancer with a poor prognosis. The occurrence of bilateral IBC in a short period of time is extremely rare. In this case report, a 54-year-old woman diagnosed with invasive ductal carcinoma of the left breast underwent lumpectomy, lymph node dissection, chemotherapy, and radiotherapy but opted against trastuzumab treatment. Four years later, she experienced bilateral breast inflammation, skin changes, edema, and heat (calor). Biopsies confirmed breast cancer metastasis to both breasts. Whole-Exome Sequencing revealed genetic mutations, including PIK3C...
Source: Frontiers in Oncology - January 12, 2024 Category: Cancer & Oncology Source Type: research

Clinical outcomes after 1 versus 2-3 lines of neoadjuvant therapy in stage III inflammatory breast cancer
ConclusionsAmong stage III IBC patients, pCR rates were similar, irrespective of the NAC lines number, and BCFS and OS were comparable with pCR after 1L and 2-3L. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - December 28, 2023 Category: Cancer & Oncology Source Type: research

Bladder metastasis from inflammatory breast cancer presenting with hematuria and hydronephrosis
We report a rare case of a 56-year-old Ukrainian female with inflammatory breast cancer (IBC) who underwent neoadjuvant chemoradiation and left radical mastectomy with her clinical course complicated by disease recurrence with bone and bladder metastases 2.5 years after her initial diagnosis. We highlight the presentation and diagnosis of genitourinary involvement of metastatic IBC, which has not previously been described in the literature.PMID:38104333 (Source: Canadian Journal of Urology)
Source: Canadian Journal of Urology - December 17, 2023 Category: Urology & Nephrology Authors: Halle E Foss Jessica Bulafka Nneamaka Nwaoduah Mihir S Shah Source Type: research